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Abstract
The phenotypically indistinguishable Acinetobacter baumannii and Acinetobacter nosocomialis have become leading pathogens causing noso-
comial pneumonia in critically ill patients. A. baumannii and A. nosocomialis nosocomial pneumonias were grouped as a single clinical entity
previously. This study aimed to determine whether they are the same or a different clinical entity. A total of 121 patients with A. bau-
mannii and 131 with A. nosocomialis bacteremic nosocomial pneumonia were included during an 8-year period. Despite the similar Charl-
son co-morbidity scores at admission, patients with A. baumannii pneumonia were more likely to have abnormal haematological findings,
lobar pneumonia, significantly higher Acute Physiology and Chronic Health Evaluation II scores and higher frequency of shock at the
onset of bacteraemia than those with A. nosocomialis pneumoni. A. baumannii isolates were resistant to more classes of antimicrobials,
except colistin, and therefore the patients with A. baumannii pneumonia were more likely to receive inappropriate antimicrobial therapy.
The 14-day mortality was significantly higher in patients with A. baumannii pneumonia (34.7% vs. 15.3%, p 0.001). A. baumannii was an
independent risk factor for mortality (OR, 2.03; 95% CI, 1.05–3.90; p 0.035) in the overall cohort after adjustment for other risk factors
for death, including inappropriate antimicrobial therapy. The results demonstrated the difference in clinical presentation, microbial char-
acteristics and outcomes between A. baumannii and A. nosocomialis nosocomial pneumonia, and supported that they are two distinct clin-
ical entities.
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Introduction
The phenotypically indistinguishable Acinetobacter baumannii,
Acinetobacter nosocomialis (formerly Acinetobacter genomic
species 13TU) and Acinetobacter pittii (formerly Acinetobacter
genomic species 3) are grouped as the A. baumannii (Ab)
group [1,2] and have emerged as leading pathogens of noso-
comial pneumonia in critically ill patients [3,4]. To date, there
is controversy over whether Ab group pneumonia results in
higher mortality [5–7] or inappropriate antimicrobial therapy
affects the mortality of patients with Ab group pneumonia
[8,9].
The pneumonia caused by phenotypically identified ‘A. bau-
mannii’ described in many studies actually comprises pneu-
monia caused by either one of the Acinetobacter species in
the Ab group [8,10]. Recently, several studies reported that
there are differences in antimicrobial resistance and outcome
between A. baumannii and other Acinetobacter species in the
Ab group [11–13]. It is unclear whether pneumonia caused
by these different Acinetobacter species can be considered as
a single clinical entity, or they are different in clinical presen-
tation, microbial characteristics and outcomes.
Acinetobacter baumannii and A. nosocomialis are the two
most commonly isolated Acinetobacter species in clinical set-
tings [14] and account for more than 80% of infections caused
by the Ab group [11,12,15,16]. In this study, the clinical
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characteristics, microbiological findings and final outcomes of
a large number of patients with bacteraemic nosocomial pneu-
monia caused by A. baumannii and A. nosocomialis were analy-
sed to determine whether nosocomial pneumonia caused by
these two Acinetobacter species is a single or distinct clinical
entity.
Materials and Methods
Study population
The study was conducted at Taipei Veterans General Hospital
(T-VGH) during an 8-year period from July 2000 to August
2008. T-VGH is a 2900-bed tertiary-care teaching hospital
located in Taipei, Taiwan. Charts were reviewed for all
patients with at least one positive blood culture for A. bau-
mannii or A. nosocomialis who had symptoms and signs of
infection. Only the first blood culture from patients with two
or more positive blood cultures was included. The criteria
for inclusion [17] in this study were (i) at least one positive
respiratory sample (sputum, bronchoalveolar lavage or pleural
effusion) for the Ab group obtained within 48 h before or
after the first positive blood culture; (ii) a clinical course com-
patible with the diagnosis of pneumonia, including a new pul-
monary infiltrate plus one additional criterion (fever ‡38C,
blood leukocytosis ‡10 000 cells/mm3 or leucopenia £3000
cells/mm3), together with one or more of the following con-
ditions: new cough, change of color of sputum, chest pain,
and dyspnoea; and (iii) that the positive blood culture was
not related to another source of infection. Patients <18 years
of age and those with incomplete medical records were
excluded. The protocol was approved by the T-VGH Institu-
tional Review Board with a waiver of informed consent.
Microbiological studies
The presumptive identification of the isolates to the level of
the Ab group was performed with the API ID 32 GN system
(bioMe´rieux, Marcy l’Etoile, France) or Vitek 2 system (bio-
Me´rieux). A multiplex-PCR method was used to identify
A. baumannii to the genomic species level [18]. Isolates iden-
tified as non- A. baumannii species of Acinetobacter were iden-
tified to the genomic species level by 16S–23S ribosomal
DNA intergenic spacer sequence analysis [19]. Antimicrobial
susceptibilities were determined by the agar dilution method
according to the Clinical Laboratory Standards Institute
(CLSI) [20]. Multidrug resistance was defined as resistance to
three or more of the following classes of antimicrobial
agents: antipseudomonal cephalosporins, antipseudomonal
carbapenems, ampicillin/sulbactam, fluoroquinolones and am-
inoglycosides [1].
Data collection
Medical records were reviewed to extract clinical informa-
tion, including demographic characteristics, underlying dis-
eases, Charlson [21] co-morbidity score, duration of stay in
an intensive care unit (ICU), length of hospital stay, time of
receipt, dose and route of administration of individual anti-
microbials, the mechanical ventilation, central venous cathe-
ters, a nasogastric tube, or a foley catheter at the time of
onset of bacteremi A. Community-acquired pneumonia
(CAP), healthcare-associated pneumonia (HCAP), nosoco-
mial pneumonia and ventilator-associated pneumonia (VAP)
were defined according to the 2005 American Thoracic
Society/Infectious Diseases Society of America (ATS/IDSA)
guidelines [22]. Chronic lung diseases other than chronic
obstructive pulmonary disease (COPD) included asthma,
bronchiectasis, pulmonary fibrosis and old pulmonary tuber-
culosis [23]. Immunosuppressive therapy was defined as
receipt of cytotoxic agents within 6 weeks, or corticoster-
oids at a dosage equivalent to or higher than 10 mg of pred-
nisolone daily for more than 5 days within 4 weeks prior to
the onset of bacteremi A. Neutropenia was defined as an
absolute neutrophil count <500 per mm3. Recent surgery
was defined as operations performed within 4 weeks prior
to the onset of bacteremi A. Chronic kidney disease was
defined as an estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73 m2. Polymicrobial bacteraemia was defined
as isolation of one or more microorganisms other than
A. baumannii or A. nosocomialis from blood during the same
bacteraemic episode. The illness severity was evaluated using
the Acute Physiology and Chronic Health Evaluation II
(APACHE II) score [24] within 24 h prior to bacteraemia
onset.
Appropriate antimicrobial therapy was defined as adminis-
tration of at least one antimicrobial agent, to which the caus-
ative pathogen was susceptible, within 48 h after the onset
of bacteraemia, with an approved route and dosage for end-
organ(s) function. Antimicrobial therapy that did not meet
this definition was considered as inappropriate. Monotherapy
with an aminoglycoside was not considered as an appropriate
therapy. The primary outcome measure was all-cause 14-day
mortality following the onset of A. baumannii or A. nosocomi-
alis bacteraemia, respectively.
Statistical analysis
To assess differences, the chi-square test with Yate’s correc-
tion or Fisher’s exact test was used to compare the discrete
variables; the Student’s t-test or Mann–Whitney rank sum
test was used to analyse continuous variables. Logistic
regression models were used to explore independent risk
factors for 14-day mortality. Univariate analyses were per-
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formed separately for each of the risk factor variables to
ascertain the odds ratio (OR) and 95% confidence interval
(CI). All biologically plausible variables with a p value of
£0.20 in the univariate analysis were considered for inclusion
in the logistic regression model for the multivariate analysis.
A backward selection process was utilized. Time to mortality
was analysed using Kaplan–Meier survival analysis. A p value
<0.05 was considered statistically significant. All the analyses
were processed with the Statistical Package for the Social
Sciences (SPSS) software version 18.0 (SPSS, Chicago, IL,
USA).
Results
During the study period 770 patients were found to have
had at least one episode of bacteraemia caused by the Ab
group. Following genomic species analysis, 353 (45.8%) and
333 (43.2%) patients were identified as having had bactera-
emia caused by A. baumannii and A. nosocomialis, respectively.
We excluded 129 patients with polymicrobial bacteraemia
and 288 patients with a positive blood culture attributable to
another source of infection. Eight patients with community-
TABLE 1. Demographic and clini-
cal characteristics of patients with
bacteraemic nosocomial pneumo-
nia caused by Acinetobacter bau-
mannii and Acinetobacter
nosocomialis
Demographic or characteristic
A. baumannii
(n = 121)
A. nosocomialis
(n = 131) p value
Age, in years 74.0 (58–80) 77 (65–83) 0.05
Gender, male 93 (76.9) 101 (77.1) >0.99
Acquired in ICU 86 (71.1) 92 (70.2) 0.99
Ventilator-associated pneumonia 85 (70.2) 93 (71.0) >0.99
Days of hospitalization prior to culture 23 (11–40) 17 (11–31) 0.14
Co-morbidity
Charlson co-morbidity score 3 (2–5) 3 (2–5) 0.77
Hypertension 57 (47.1) 79 (60.3) 0.05
Coronary artery disease 22 (18.2) 24 (18.3) >0.99
Congestive heart failure 21 (17.4) 22 (16.5) >0.99
Cerebral vascular disease 27 (22.3) 34 (26.0) 0.60
COPD 28 (23.1) 40 (30.5) 0.24
Other chronic lung disease 18 (14.9) 14 (10.7) 0.42
Alcoholism 15 (12.4) 7 (5.3) 0.08
Liver cirrhosis 8 (6.6) 10 (7.6) 0.94
Chronic kidney disease 38 (31.4) 37 (28.2) 0.68
Type 2 diabetes mellitus 40 (33.1) 47 (35.9) 0.74
Collagen vascular disease 10 (8.3) 2 (1.5) 0.03
Usage of immunosupressants
Cytotoxic chemotherapy 19 (15.7) 13 (9.9) 0.24
Corticosteroids 24 (19.8) 13 (9.9) 0.04
Malignancy 41 (33.9) 39 (29.8) 0.57
Recent surgery 38 (31.4) 52 (39.7) 0.22
Trauma 4 (3.3) 11 (8.4) 0.15
Procedurea
Central venous catheter 80 (66.1) 83 (63.4) 0.75
Foley catheter 89 (73.6) 93 (71.0) 0.75
Haemodialysis 14 (11.6) 13 (9.9) 0.83
Nasogastric tube 111 (91.7) 100 (76.3) 0.002
Thoracic drain 7 (5.8) 12 (9.2) 0.44
Endotracheal tube or tracheostomy 103 (85.1) 103 (78.6) 0.24
Mechanical ventilation 90 (74.4) 94 (71.8) 0.74
Shocka 77 (63.6) 62 (47.3) 0.01
Laboratory parametersa
WBC count <4000/mm3, >12 000/mm3, or >10% bands 96 (70.6) 75 (56.4) 0.02
Haemoglobin, g/dL 9.2 (8.3–10.5) 10.1 (9.0–11.2) <0.001
Platelet count, ·103 cells/mm3 136 (54.8–222) 170 (96–255) 0.04
APACHE II scorea 26 (21–34) 24 (18–30) 0.009
Radiological features
Lobar consolidation 13 (10.7) 4 (3.1) 0.03
Bilateral radiological involvement 89 (73.6) 93 (71.0) 0.75
Pleural effusion 40 (33.1) 46 (35.1) 0.83
Appropriate antimicrobial therapy 32 (26.4) 69 (52.7) <0.001
Outcome
14-day mortality 42 (34.7) 20 (15.3) 0.001
In-hospital mortality 79 (65.3) 53 (40.5) <0.001
Time to death, days 9 (1–32) 27 (8.5–60.5) 0.003
Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical vari-
ables.
ICU, intensive care units; COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology and Chronic
Health Evaluation; WBC, white blood cell.
aAt the time the blood culture was obtained.
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acquired A. baumannii pneumonia, which is a distinct clinical
entity, were excluded [23,25]. We also excluded nine
patients with HCAP (seven caused by A. baumannii and two
by A. nosocomialis). The final population that met the criteria
for entry into the study consisted of 121 patients with
A. baumannii and 131 patients with A. nosocomialis nosocomial
pneumonia.
The demographic and clinical characteristics of the study
patients are summarized in Table 1. Patients with A. bauman-
nii had more collagen vascular diseases, and more frequently
received corticosteroids and had nasogastric tubes than
those with A. nosocomialis.
The Charlson co-morbidity scores on admission were sim-
ilar for the two Acinetobacter species. However, patients with
A. baumannii had significantly higher APACHE II scores (p
0.003) and more frequently presented with shock at the time
positive blood cultures were obtained. Patients with A. bau-
mannii had lower haemoglobin levels and platelet counts, and
more frequently presented with leukocytosis or leucopenia,
but they did not have more haematological malignancy (data
not shown). Pulmonary lobar consolidation was significantly
more frequent in patients with A. baumannii pneumonia (p
0.03), while pleural effusion and bilateral lung involvement
were about the same with both Acinetobacter species.
The antimicrobial susceptibility profiles of the clinical iso-
lates of A. baumannii and A. nosocomialis are shown in
Table 2. A. baumannii exhibited significantly higher rates of
resistance to all antimicrobials tested, with the exception of
colistin. None of the A. baumannii isolates were resistant to
colistin. In contrast, 26.7% of the A. nosocomialis isolates
were resistant to colistin (p <0.001). Patients with bacterae-
mic pneumonia caused by A. baumannii were accordingly
more likely to receive inappropriate antimicrobial therapy.
The 14-day mortality was significantly higher for patients
with bacteraemic pneumonia caused by A. baumannii than for
A. nosocomialis (34.7% vs. 15.3%, p 0.001). The median time
to death was significantly shorter for A. baumannii (9 days; in-
terquartile range, 1–32 days) than A. nosocomialis pneumonia
(27 days; interquartile range, 8.5–60.5 days) (p 0.003). Kap-
lan–Meier survival curves reflected the early occurrence of
death within a few days following pneumonia for patients
with A. baumannii. This was followed by slightly higher rates
of death for A. baumannii than A. nosocomialis species thereaf-
ter (p <0.001, by log-rank test) (Fig. 1).
In order to clarify the influence of different Acinetobacter
species on 14-day mortality, multivariate logistic regression
analysis was performed for the overall cohort to identify
independent risk and protective factors for mortality
(Table 3). Notably, A. baumannii was an independent risk fac-
tor for mortality (OR, 2.03; 95% CI, 1.05–3.90; p 0.035).
Discussion
This study clearly demonstrates significant differences in the
clinical features, microbial characteristics and outcome of
bacteraemic nosocomial pneumonia caused by A. baumannii
and A. nosocomialis. Compared with patients with A. nosocomi-
alis pneumonia, patients with A. baumannii pneumonia have
more collagen vascular disease and use of corticosteroids.
Patients with A. baumannii were significantly more likely to
have more severe illness as determined by APACHE II score,
greater frequency of shock, abnormal haematological findings,
lobar pneumonia, antimicrobial resistance, inappropriate use
of antimicrobials, shorter time to death and higher mortality.
These findings support the concept that bacteraemic pneu-
monias caused by A. baumannii and A. nosocomialis should be
considered as two distinct clinical entities.
The shorter time to death and higher mortality of patients
infected with A. baumannii compared with A. nosocomialis may
be attributed to an unfavourable underlying disease of the
TABLE 2. Comparison of antimicrobial susceptibilities of
Acinetobacter baumannii and Acinetobacter nosocomialis iso-
lates
Antimicrobial
agent
Resistance, n (%)
p value
A. baumannii
(n = 121)
A. nosocomialis
(n = 131)
Amikacin 108 (89.3) 53 (40.5) <0.001
Gentamicin 110 (90.9) 84 (64.1) <0.001
Ceftazidime 110 (90.9) 39 (29.8) <0.001
Cefepime 82 (67.8) 31 (23.7) <0.001
Ampicillin/sulbactam 68 (56.2) 40 (30.5) <0.001
Ciprofloxacin 111 (91.7) 15 (11.5) <0.001
Imipenem 49 (40.5) 28 (21.4) 0.002
Tigecycline 18 (14.9) 7 (5.3) 0.02
Colistin 0 (0) 35 (26.7) <0.001
Multidrug resistance 112 (92.6) 63 (48.1) <0.001
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FIG. 1. Kaplan–Meier survival curves for patients with Acinetobacter
baumannii and Acinetobacter nosocomialis bacteraemic nosocomial
pneumonia.
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patients, higher frequency of inappropriate antimicrobial ther-
apy in the former group and possibly higher pathogenicity of
A. baumannii [11,12]. Our study showed that although the
chronic co-morbidity scores of patients at admission were
similar between the two groups, pneumonia caused by A. bau-
mannii was more severe than that caused by A. nosocomialis at
the onset of bacteremi A. In addition, A. baumannii is an inde-
pendent risk factor for mortality after adjustment for other
risk factors for death, including inappropriate antimicrobial
therapy. The result once again indicated a higher pathogenic-
ity of A. baumannii. Based on the results one could assume
that previous papers reporting a negligible attributable mor-
tality of the Ab group [10] might include a large proportion
of patients with infections due to A. nosocomialis, while papers
reporting a considerable attributable mortality [6] might
include mostly patients with real A. baumannii infections.
Our findings that higher resistance rates of all antimicrobi-
als except colistin were observed in A. baumannii isolates
than in A. nosocomialis [11,15,26] were responsible for the
increasing chance of receiving an inappropriate antimicrobial
therapy in patients infected with A. baumannii. This might also
contribute to the higher mortality in A. baumannii, especially
in those with higher APACHE II scores [27].
In conclusion, we recommend that nosocomial pneumonia
caused by A. baumannii and A. nosocomialis should be consid-
ered as two different clinical entities.
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